Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Andrew Lawrence Frelinger, Ph.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Spurgeon BEJ, Frelinger AL. Platelet Phenotyping by Full Spectrum Flow Cytometry. Curr Protoc. 2023 Feb; 3(2):e687. PMID: 36779850.
    Citations:    Fields:    Translation:Cells
  2. Mezzano D, Harrison P, Frelinger AL, Mumford AD, Noris P, Lordkipanidzé M, Gresele P. Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost. 2022 09; 20(9):2127-2135. PMID: 35770723.
    Citations:    Fields:    Translation:HumansCells
  3. Li M, Wang X, Lin X, Bian X, Jing R, Frelinger A, Zhang A. Comparison and Analysis of Gut Microbiota in Children With IgA Vasculitis With Different Clinical Symptoms. Front Pediatr. 2021; 9:800677. PMID: 35071141; PMCID: PMC8778574.
    Citations: 1     
  4. Spurgeon BEJ, Frelinger AL. Comprehensive phenotyping of human platelets by single-cell cytometry. Cytometry A. 2022 04; 101(4):290-297. PMID: 34997669.
    Citations: 1     Fields:    Translation:HumansCells
  5. Poli V, Di Gioia M, Sola-Visner M, Granucci F, Frelinger AL, Michelson AD, Zanoni I. Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia. Immunity. 2022 02 08; 55(2):224-236.e5. PMID: 34995475.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  6. Gremmel T, Michelson AD, Wadowski PP, Pultar J, Weikert C, Tscharre M, Lee S, Panzer S, Frelinger AL. Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization. Atherosclerosis. 2021 12; 339:12-19. PMID: 34808540.
    Citations: 1     Fields:    Translation:HumansCells
  7. Revel-Vilk S, Naamad M, Frydman D, Freund MR, Dinur T, Istaiti M, Becker-Cohen M, Falk R, Broide E, Michelson AD, Frelinger AL, Zimran A. Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher Disease. Thromb Haemost. 2022 06; 122(6):951-960. PMID: 34507369.
    Citations: 3     Fields:    Translation:HumansCells
  8. Frelinger AL, Rivera J, Connor DE, Freson K, Greinacher A, Harrison P, Kunishima S, Lordkipanidzé M, Michelson AD, Ramström S, Gresele P. Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost. 2021 12; 19(12):3193-3202. PMID: 34580997.
    Citations: 4     Fields:    Translation:Humans
  9. Spurgeon BEJ, Linden MD, Michelson AD, Frelinger AL. Immunophenotypic Analysis of Platelets by Flow Cytometry. Curr Protoc. 2021 Jun; 1(6):e178. PMID: 34170638.
    Citations: 3     Fields:    Translation:Cells
  10. Spurgeon BEJ, Michelson AD, Frelinger AL. Platelet Immunophenotyping by High-Dimensional Mass Cytometry. Curr Protoc. 2021 May; 1(5):e112. PMID: 33950581.
    Citations: 1     Fields:    Translation:HumansCells
  11. Neculaes B, Frelinger AL, Gerrits AJ, Gremmel T, Forde EE, Klopman S, Carmichael SL, Michelson AD. Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin. PLoS One. 2021; 16(4):e0249209. PMID: 33891598.
    Citations: 1     Fields:    Translation:Humans
  12. Pittman DD, Hines PC, Beidler D, Rybin D, Frelinger AL, Michelson AD, Liu K, Gao X, White J, Zaidi AU, Charnigo RJ, Callaghan MU. Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers. Blood. 2021 04 15; 137(15):2010-2020. PMID: 33067606.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  13. Berg DD, Yeh RW, Mauri L, Morrow DA, Kereiakes DJ, Cutlip DE, Gao Q, Jarolim P, Michelson AD, Frelinger AL, Cange AL, Sabatine MS, O'Donoghue ML. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr; 51(3):675-681. PMID: 32683645.
    Citations: 4     Fields:    Translation:Humans
  14. Croteau SE, Frelinger AL, Gerrits AJ, Michelson AD. Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency. J Thromb Haemost. 2021 04; 19(4):976-982. PMID: 33370471.
    Citations: 2     Fields:    Translation:HumansCells
  15. Spurgeon BEJ, Michelson AD, Frelinger AL. Platelet mass cytometry: Optimization of sample, reagent, and analysis parameters. Cytometry A. 2021 02; 99(2):170-179. PMID: 33399275.
    Citations: 3     Fields:    Translation:HumansCells
  16. Mazzeffi M, Tanaka K, Wu YF, Zhang A, Kareddy N, Tadjou Tito E, Rock P, Michelson AD, Frelinger AL. Platelet surface GPIba, activated GPIIb-IIIa, and P-selectin levels in adult veno-arterial extracorporeal membrane oxygenation patients. Platelets. 2022 Jan 02; 33(1):116-122. PMID: 33284729.
    Citations: 1     Fields:    Translation:Humans
  17. Harrison P, Lordkipanidzé M, Frelinger AL, Thomas MR, Watson SP. Platelet count and disease - editorial policy. Platelets. 2020 11 16; 31(8):969-970. PMID: 33969797.
    Citations:    Fields:    
  18. Harrison P, Lordkipanidzé M, Frelinger AL, Thomas MR, Watson SP. Platelet count and disease - editorial policy. Platelets. 2020 Nov 16; 31(8):969-970. PMID: 32762569.
    Citations:    Fields:    
  19. Hanrahan JP, Seferovic JP, Wakefield JD, Wilson PJ, Chickering JG, Jung J, Carlson KE, Zimmer DP, Frelinger AL, Michelson AD, Morrow L, Hall M, Currie MG, Milne GT, Profy AT. An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Diabetologia. 2020 04; 63(4):733-743. PMID: 31858186.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  20. Blair TA, Frelinger AL. Platelet surface marker analysis by mass cytometry. Platelets. 2020 Jul 03; 31(5):633-640. PMID: 31544564.
    Citations: 6     Fields:    Translation:HumansCells
  21. Garner AL, Frelinger AL, Gerrits AJ, Gremmel T, Forde EE, Carmichael SL, Michelson AD, Neculaes VB. Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting. Med Hypotheses. 2019 Apr; 125:100-105. PMID: 30902134.
    Citations: 2     Fields:    Translation:HumansAnimals
  22. Charnigo RJ, Beidler D, Rybin D, Pittman DD, Tan B, Howard J, Michelson AD, Frelinger AL, Clarke N. PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study. Clin Transl Sci. 2019 03; 12(2):180-188. PMID: 30597771.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  23. Smolensky Koganov E, Michelson AD, Yanachkov IB, Yanachkova MI, Wright GE, Przyklenk K, Frelinger AL. Publisher Correction: GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 Nov 29; 8(1):17580. PMID: 30498241.
    Citations:    Fields:    
  24. Michelson AD, Smolensky Koganov E, Forde EE, Carmichael SL, Frelinger AL. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease. J Thromb Haemost. 2018 12; 16(12):2515-2519. PMID: 30264918.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  25. Frelinger AL, Gachet C, Mumford AD, Noris P, Mezzano D, Harrison P, Gresele P. Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH. J Thromb Haemost. 2018 11; 16(11):2341-2346. PMID: 30284374.
    Citations: 3     Fields:    Translation:Humans
  26. Smolensky Koganov E, Michelson AD, Yanachkov IB, Yanachkova MI, Wright GE, Przyklenk K, Frelinger AL. GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 09 28; 8(1):14529. PMID: 30266987.
    Citations: 3     Fields:    Translation:HumansAnimals
  27. Frelinger AL, Gerrits AJ, Neculaes VB, Gremmel T, Torres AS, Caiafa A, Carmichael SL, Michelson AD. Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology. PLoS One. 2018; 13(9):e0203557. PMID: 30256831.
    Citations: 3     Fields:    Translation:Humans
  28. Blair TA, Michelson AD, Frelinger AL. Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia. Sci Rep. 2018 07 09; 8(1):10300. PMID: 29985398.
    Citations: 17     Fields:    Translation:HumansCells
  29. Gremmel T, Michelson AD, Frelinger AL, Bhatt DL. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost. 2018 Jul; 2(3):439-449. PMID: 30046748; PMCID: PMC6046593.
    Citations: 18     
  30. Frelinger AL. Using flow cytometry to monitor glycoprotein IIb-IIIa activation. Platelets. 2018 Nov; 29(7):670-676. PMID: 29799301.
    Citations: 3     Fields:    Translation:HumansCells
  31. Gerrits AJ, Jakubowski JA, Michelson AD, Frelinger AL. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply. J Thromb Haemost. 2018 03; 16(3):607-608. PMID: 29314666.
    Citations:    Fields:    Translation:Cells
  32. Frelinger AL, Grace RF, Gerrits AJ, Carmichael SL, Forde EE, Michelson AD. Platelet Function in ITP, Independent of Platelet Count, Is Consistent Over Time and Is Associated with Both Current and Subsequent Bleeding Severity. Thromb Haemost. 2018 01; 118(1):143-151. PMID: 29304534.
    Citations: 10     Fields:    Translation:HumansCells
  33. Nwankwo JO, Gremmel T, Gerrits AJ, Mithila FJ, Warburton RR, Hill NS, Lu Y, Richey LJ, Jakubowski JA, Frelinger AL, Chishti AH. Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease. Thromb Res. 2017 Dec; 160:58-65. PMID: 29101791; PMCID: PMC5723238.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  34. Haynes RL, Frelinger AL, Giles EK, Goldstein RD, Tran H, Kozakewich HP, Haas EA, Gerrits AJ, Mena OJ, Trachtenberg FL, Paterson DS, Berry GT, Adeli K, Kinney HC, Michelson AD. High serum serotonin in sudden infant death syndrome. Proc Natl Acad Sci U S A. 2017 07 18; 114(29):7695-7700. PMID: 28674018; PMCID: PMC5530643.
    Citations: 22     Fields:    Translation:Humans
  35. Bhatt DL, Grosser T, Dong JF, Logan D, Jeske W, Angiolillo DJ, Frelinger AL, Liang J, Cryer B, Marathi U. Reply: Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis? J Am Coll Cardiol. 2017 06 13; 69(23):2879. PMID: 28595709.
    Citations:    Fields:    Translation:Humans
  36. Gerrits AJ, Jakubowski JA, Sugidachi A, Michelson AD, Frelinger AL. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor. J Thromb Haemost. 2017 05; 15(5):858-867. PMID: 28092426.
    Citations: 3     Fields:    Translation:HumansCells
  37. Bhatt DL, Grosser T, Dong JF, Logan D, Jeske W, Angiolillo DJ, Frelinger AL, Lei L, Liang J, Moore JE, Cryer B, Marathi U. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017 Feb 14; 69(6):603-612. PMID: 28089180.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  38. Gerrits AJ, Frelinger AL, Michelson AD. Whole Blood Analysis of Leukocyte-Platelet Aggregates. Curr Protoc Cytom. 2016 10 10; 78:6.15.1-6.15.10. PMID: 27723089.
    Citations: 9     Fields:    Translation:HumansCells
  39. Frelinger AL, Gerrits AJ, Garner AL, Torres AS, Caiafa A, Morton CA, Berny-Lang MA, Carmichael SL, Neculaes VB, Michelson AD. Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich Plasma. PLoS One. 2016; 11(8):e0160933. PMID: 27556645.
    Citations: 8     Fields:    Translation:HumansCells
  40. Jain A, van der Meer AD, Papa AL, Barrile R, Lai A, Schlechter BL, Otieno MA, Louden CS, Hamilton GA, Michelson AD, Frelinger AL, Ingber DE. Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium. Biomed Microdevices. 2016 08; 18(4):73. PMID: 27464497.
    Citations: 49     Fields:    Translation:HumansCells
  41. Carreras ET, Hochholzer W, Frelinger AL, Nordio F, O'Donoghue ML, Wiviott SD, Angiolillo DJ, Michelson AD, Sabatine MS, Mega JL. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial. Thromb Haemost. 2016 07 04; 116(1):69-77. PMID: 27009617.
    Citations: 8     Fields:    Translation:Humans
  42. Gremmel T, Frelinger AL, Michelson AD. Platelet Physiology. Semin Thromb Hemost. 2016 Apr; 42(3):191-204. PMID: 26926581.
    Citations: 82     Fields:    Translation:HumansCells
  43. Gremmel T, Yanachkov IB, Yanachkova MI, Wright GE, Wider J, Undyala VV, Michelson AD, Frelinger AL, Przyklenk K. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol. 2016 Mar; 36(3):501-9. PMID: 26743169; PMCID: PMC4767596.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  44. Gremmel T, Michelson AD, Frelinger AL. In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. Platelets. 2016 Jun; 27(4):308-16. PMID: 26556638.
    Citations: 4     Fields:    Translation:HumansCells
  45. Yanachkov IB, Chang H, Yanachkova MI, Dix EJ, Berny-Lang MA, Gremmel T, Michelson AD, Wright GE, Frelinger AL. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem. 2016 Jan 01; 107:204-18. PMID: 26588064.
    Citations: 12     Fields:    Translation:HumansAnimals
  46. Brun C, Daali Y, Combescure C, Zufferey A, Michelson AD, Fontana P, Reny JL, Frelinger AL. Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. Platelets. 2016; 27(3):196-202. PMID: 26270593.
    Citations: 7     Fields:    Translation:HumansCells
  47. Gremmel T, Frelinger AL, Michelson AD. Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization. PLoS One. 2015; 10(8):e0134599. PMID: 26237513.
    Citations: 4     Fields:    Translation:Humans
  48. Gerrits AJ, Leven EA, Frelinger AL, Brigstocke SL, Berny-Lang MA, Mitchell WB, Revel-Vilk S, Tamary H, Carmichael SL, Barnard MR, Michelson AD, Bussel JB. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood. 2015 Sep 10; 126(11):1367-78. PMID: 26224646; PMCID: PMC4729539.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  49. Frelinger AL, Grace RF, Gerrits AJ, Berny-Lang MA, Brown T, Carmichael SL, Neufeld EJ, Michelson AD. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015 Aug 13; 126(7):873-9. PMID: 26138687; PMCID: PMC4536541.
    Citations: 41     Fields:    Translation:HumansCells
  50. Frelinger AL, Torres AS, Caiafa A, Morton CA, Berny-Lang MA, Gerrits AJ, Carmichael SL, Neculaes VB, Michelson AD. Platelet-rich plasma stimulated by pulse electric fields: Platelet activation, procoagulant markers, growth factor release and cell proliferation. Platelets. 2016; 27(2):128-35. PMID: 26030682.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  51. Mumford AD, Frelinger AL, Gachet C, Gresele P, Noris P, Harrison P, Mezzano D. A review of platelet secretion assays for the diagnosis of inherited platelet secretion disorders. Thromb Haemost. 2015 Jul; 114(1):14-25. PMID: 25879272.
    Citations: 23     Fields:    Translation:HumansCells
  52. Torres AS, Caiafa A, Garner AL, Klopman S, LaPlante N, Morton C, Conway K, Michelson AD, Frelinger AL, Neculaes VB. Platelet activation using electric pulse stimulation: growth factor profile and clinical implications. J Trauma Acute Care Surg. 2014 Sep; 77(3 Suppl 2):S94-S100. PMID: 25159369.
    Citations: 7     Fields:    Translation:HumansAnimals
  53. Jakubowski JA, Zhou C, Winters KJ, Lachno DR, Howard J, Payne CD, Mant T, Jurcevic S, Frelinger AL. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease. Platelets. 2015; 26(5):474-9. PMID: 25140584.
    Citations: 3     Fields:    Translation:HumansCells
  54. Hochholzer W, Ruff CT, Mesa RA, Mattimore JF, Cyr JF, Lei L, Frelinger AL, Michelson AD, Berg DD, Angiolillo DJ, O'Donoghue ML, Sabatine MS, Mega JL. Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. J Am Coll Cardiol. 2014 Jul 29; 64(4):361-8. PMID: 25060370.
    Citations: 21     Fields:    Translation:Humans
  55. Berny-Lang MA, Darling CE, Frelinger AL, Barnard MR, Smith CS, Michelson AD. Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome? Int J Lab Hematol. 2015 Feb; 37(1):112-9. PMID: 24806286.
    Citations: 4     Fields:    Translation:HumansCells
  56. Chang H, Yanachkov IB, Dix EJ, Yanachkova M, Li Y, Barnard MR, Wright GE, Michelson AD, Frelinger AL. Antiplatelet activity, P2Y1 and P2Y12 inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'?-P¹ ,P4-dithio-P²,P³-chloromethylenetetraphosphate. PLoS One. 2014; 9(4):e94780. PMID: 24722456.
    Citations: 7     Fields:    Translation:Humans
  57. Jakubowski JA, Zhou C, Jurcevic S, Winters KJ, Lachno DR, Frelinger AL, Gupta N, Howard J, Payne CD, Mant TG. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb Res. 2014 Feb; 133(2):190-5. PMID: 24368019.
    Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
  58. Chang H, Shih LY, Michelson AD, Dunn P, Frelinger AL, Wang PN, Kuo MC, Lin TL, Wu JH, Tang TC. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. Acta Haematol. 2013; 130(3):181-7. PMID: 23751441.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  59. Jakubowski JA, Zhou C, Small DS, Winters KJ, Lachno DR, Frelinger AL, Howard J, Mant TG, Jurcevic S, Payne CD. A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol. 2013 Jun; 75(6):1433-44. PMID: 23171128; PMCID: PMC3690102.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  60. Smith BW, Rozelle SS, Leung A, Ubellacker J, Parks A, Nah SK, French D, Gadue P, Monti S, Chui DH, Steinberg MH, Frelinger AL, Michelson AD, Theberge R, McComb ME, Costello CE, Kotton DN, Mostoslavsky G, Sherr DH, Murphy GJ. The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. Blood. 2013 Jul 18; 122(3):376-85. PMID: 23723449; PMCID: PMC3716202.
    Citations: 62     Fields:    Translation:HumansAnimalsCells
  61. Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity. J Am Heart Assoc. 2013 May 15; 2(3):e000026. PMID: 23676293.
    Citations: 8     Fields:    Translation:HumansCells
  62. Psaila B, Bussel JB, Frelinger AL, Michelson AD. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia: a reply to a rebuttal. J Thromb Haemost. 2013 May; 11(5):1002-3. PMID: 23496753.
    Citations: 1     Fields:    Translation:HumansCells
  63. Frelinger AL, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, Barnard MR, Heeney MM, Michelson AD. Platelet activation and inhibition in sickle cell disease (pains) study. Platelets. 2014; 25(1):27-35. PMID: 23469943.
    Citations: 22     Fields:    Translation:HumansCells
  64. Wun T, Soulieres D, Frelinger AL, Krishnamurti L, Novelli EM, Kutlar A, Ataga KI, Knupp CL, McMahon LE, Strouse JJ, Zhou C, Heath LE, Nwachuku CE, Jakubowski JA, Riesmeyer JS, Winters KJ. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol. 2013 Feb 17; 6:17. PMID: 23414938.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  65. Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013 Feb 26; 61(8):872-9. PMID: 23333143.
    Citations: 49     Fields:    Translation:Humans
  66. Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost. 2013 Feb; 109(2):347-55. PMID: 23223867.
    Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
  67. Chang H, Yanachkov IB, Dix EJ, Li YF, Barnard MR, Wright GE, Michelson AD, Frelinger AL. Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. J Thromb Haemost. 2012 Dec; 10(12):2573-80. PMID: 23083103.
    Citations: 8     Fields:    Translation:HumansCells
  68. Frelinger AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012 Apr 03; 59(14):1304-11. PMID: 22464259.
    Citations: 43     Fields:    Translation:HumansCells
  69. Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, Tate C, Mathur K, Frelinger AL, Michelson AD. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012 Apr 26; 119(17):4066-72. PMID: 22294727; PMCID: PMC3350368.
    Citations: 25     Fields:    Translation:HumansCells
  70. Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011 Nov 23; 306(20):2221-8. PMID: 22088980.
    Citations: 118     Fields:    Translation:Humans
  71. Psaila B, Bussel JB, Frelinger AL, Babula B, Linden MD, Li Y, Barnard MR, Tate C, Feldman EJ, Michelson AD. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost. 2011 Nov; 9(11):2302-10. PMID: 21920014.
    Citations: 22     Fields:    Translation:HumansCells
  72. Scheer FA, Michelson AD, Frelinger AL, Evoniuk H, Kelly EE, McCarthy M, Doamekpor LA, Barnard MR, Shea SA. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors. PLoS One. 2011; 6(9):e24549. PMID: 21931750.
    Citations: 62     Fields:    Translation:Humans
  73. Frelinger AL, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, Miller DL, Jakubowski JA, Costigan TM, McCabe CH, Antman EM, Braunwald E. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost. 2011 Aug; 106(2):219-26. PMID: 21713327.
    Citations: 3     Fields:    Translation:Humans
  74. Ferrer-Marin F, Chavda C, Lampa M, Michelson AD, Frelinger AL, Sola-Visner M. Effects of in vitro adult platelet transfusions on neonatal hemostasis. J Thromb Haemost. 2011 May; 9(5):1020-8. PMID: 21320282.
    Citations: 18     Fields:    Translation:HumansCells
  75. Rahangdale S, Yeh SY, Novack V, Stevenson K, Barnard MR, Furman MI, Frelinger AL, Michelson AD, Malhotra A. The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea. J Clin Sleep Med. 2011 Apr 15; 7(2):172-8. PMID: 21509332.
    Citations: 31     Fields:    Translation:Humans
  76. Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, Zhu B, Ojeh CK, Baker BA, Effron MB. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J. 2011 Apr; 32(7):838-46. PMID: 21252171.
    Citations: 48     Fields:    Translation:Humans
  77. Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Effron MB. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010 Sep 21; 56(13):1017-23. PMID: 20846599.
    Citations: 36     Fields:    Translation:HumansCellsCTClinical Trials
  78. Frelinger AL, Barnard MR, Fox ML, Michelson AD. The Platelet Activity After Clopidogrel Termination (PACT) study. Circ Cardiovasc Interv. 2010 Oct; 3(5):442-9. PMID: 20736449.
    Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
  79. Frelinger AL. Platelet reactivity with prolonged aspirin treatment--steady going at 2 year. Circ J. 2010 Jun; 74(6):1077-8. PMID: 20472961.
    Citations:    Fields:    Translation:Humans
  80. Lajer M, Tarnow I, Michelson AD, Jorsal A, Frelinger AL, Parving HH, Rossing P, Tarnow L. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets. 2010; 21(7):525-32. PMID: 20701458.
    Citations: 9     Fields:    Translation:Humans
  81. Frelinger AL, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009 Dec 22; 120(25):2586-96. PMID: 19996015.
    Citations: 41     Fields:    Translation:HumansCells
  82. Chang H, Yanachkov IB, Michelson AD, Li Y, Barnard MR, Wright GE, Frelinger AL. Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res. 2010 Feb; 125(2):159-65. PMID: 19945153.
    Citations: 17     Fields:    Translation:HumansCells
  83. Przyklenk K, Frelinger AL, Linden MD, Whittaker P, Li Y, Barnard MR, Adams J, Morgan M, Al-Shamma H, Michelson AD. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost. 2010 Feb; 8(2):331-40. PMID: 19922435.
    Citations: 22     Fields:    Translation:AnimalsCells
  84. Tarnow I, Michelson AD, Barnard MR, Frelinger AL, Aasted B, Jensen BR, Parving HH, Rossing P, Tarnow L. Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets. 2009 Nov; 20(7):513-9. PMID: 19852691.
    Citations: 12     Fields:    Translation:HumansCells
  85. Michelson AD, Frelinger AL, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009 Jul; 30(14):1753-63. PMID: 19435740.
    Citations: 48     Fields:    Translation:HumansCells
  86. Bednarek FJ, Bean S, Barnard MR, Frelinger AL, Michelson AD. The platelet hyporeactivity of extremely low birth weight neonates is age-dependent. Thromb Res. 2009 May; 124(1):42-5. PMID: 19026437.
    Citations: 19     Fields:    Translation:HumansCells
  87. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, Michelson AD. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost. 2008 Dec; 6(12):2035-44. PMID: 18983514.
    Citations: 18     Fields:    Translation:Humans
  88. Tarnow I, Kristensen AT, Krogh AK, Frelinger AL, Barnard MR, Michelson AD. Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation. Vet Immunol Immunopathol. 2008 Jun 15; 123(3-4):345-52. PMID: 18405981.
    Citations: 4     Fields:    Translation:AnimalsCells
  89. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007 Dec 18; 116(25):2923-32. PMID: 18056526.
    Citations: 148     Fields:    Translation:HumansCTClinical Trials
  90. Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Linden MD, Tarnow I, Fox ML, Sugidachi A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost. 2008 Feb; 6(2):359-65. PMID: 18021304.
    Citations: 9     Fields:    Translation:HumansCells
  91. Linden MD, Barnard MR, Frelinger AL, Michelson AD, Przyklenk K. Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models. Thromb Res. 2008; 121(5):689-98. PMID: 17727923; PMCID: PMC2346597.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  92. Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, Sugidachi A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost. 2007 Jul; 98(1):192-200. PMID: 17598013.
    Citations: 10     Fields:    Translation:HumansCells
  93. Tarnow I, Michelson AD, Frelinger AL, Linden MD, Li Y, Fox ML, Barnard MR, O'Sullivan BP. Cystic fibrosis heterozygotes do not have increased platelet activation. Thromb Res. 2007; 121(2):159-62. PMID: 17532368.
    Citations: 2     Fields:    Translation:Humans
  94. Linden MD, Furman MI, Frelinger AL, Fox ML, Barnard MR, Li Y, Przyklenk K, Michelson AD. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost. 2007 Apr; 5(4):761-5. PMID: 17371489.
    Citations: 27     Fields:    Translation:HumansCells
  95. Harrison P, Frelinger AL, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res. 2007; 120(3):323-36. PMID: 17239428.
    Citations: 29     Fields:    Translation:HumansCells
  96. Michelson AD, Frelinger AL, Furman MI. Current options in platelet function testing. Am J Cardiol. 2006 Nov 20; 98(10A):4N-10N. PMID: 17097417.
    Citations: 36     Fields:    Translation:Humans
  97. Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, Lau WC, McLaughlin TJ, Frelinger AL. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost. 2007 Jan; 5(1):75-81. PMID: 17002661.
    Citations: 15     Fields:    Translation:HumansCells
  98. Linden MD, Whittaker P, Frelinger AL, Barnard MR, Michelson AD, Przyklenk K. Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation. J Thromb Haemost. 2006 Dec; 4(12):2670-7. PMID: 16995902.
    Citations: 14     Fields:    Translation:AnimalsCells
  99. Frelinger AL, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006 Jun 27; 113(25):2888-96. PMID: 16785341.
    Citations: 60     Fields:    Translation:HumansCells
  100. Barnard MR, Linden MD, Frelinger AL, Li Y, Fox ML, Furman MI, Michelson AD. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost. 2005 Nov; 3(11):2563-70. PMID: 16241954.
    Citations: 18     Fields:    Translation:HumansCells
  101. Frelinger AL, Michelson AD. Clopidogrel linking evaluation of platelet response variability to mechanism of action. J Am Coll Cardiol. 2005 Aug 16; 46(4):646-7. PMID: 16098429.
    Citations: 2     Fields:    Translation:HumansCells
  102. O'Sullivan BP, Linden MD, Frelinger AL, Barnard MR, Spencer-Manzon M, Morris JE, Salem RO, Laposata M, Michelson AD. Platelet activation in cystic fibrosis. Blood. 2005 Jun 15; 105(12):4635-41. PMID: 15705796.
    Citations: 32     Fields:    Translation:HumansCells
  103. Furman MI, Krueger LA, Linden MD, Fox ML, Ball SP, Barnard MR, Frelinger AL, Michelson AD. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost. 2005 Feb; 3(2):312-20. PMID: 15670038.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  104. Linden MD, Frelinger AL, Barnard MR, Przyklenk K, Furman MI, Michelson AD. Application of flow cytometry to platelet disorders. Semin Thromb Hemost. 2004 Oct; 30(5):501-11. PMID: 15497093.
    Citations: 23     Fields:    Translation:HumansCells
  105. Furman MI, Frelinger AL, Michelson AD. GPIIb/IIIa inhibitor-induced dethrombosis. J Thromb Thrombolysis. 2004 Aug; 18(1):11-7. PMID: 15744548.
    Citations: 6     Fields:    Translation:HumansAnimals
  106. Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL, Michelson AD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004 Jun 16; 43(12):2319-25. PMID: 15193700.
    Citations: 28     Fields:    Translation:HumansCells
  107. Frelinger AL, Furman MI, Barnard MR, Krueger LA, Dae MW, Michelson AD. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation. Am J Cardiol. 2003 Nov 01; 92(9):1099-101. PMID: 14583364.
    Citations: 9     Fields:    Translation:HumansCells
  108. Barnard MR, Krueger LA, Frelinger AL, Furman MI, Michelson AD. Whole blood analysis of leukocyte-platelet aggregates. Curr Protoc Cytom. 2003 May; Chapter 6:Unit 6.15. PMID: 18770779.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  109. Claytor RB, Michelson AD, Li JM, Frelinger AL, Rohrer MJ, Garnette CS, Barnard MR, Krueger LA, Furman MI. The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin. J Vasc Surg. 2003 Feb; 37(2):440-5. PMID: 12563219.
    Citations: 1     Fields:    Translation:Humans
  110. Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. Am Heart J. 2003 Feb; 145(2):e6. PMID: 12595861.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  111. Marciniak SJ, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002 Jun; 87(6):1020-5. PMID: 12083481.
    Citations: 18     Fields:    Translation:HumansCells
  112. Krueger LA, Barnard MR, Frelinger AL, Furman MI, Michelson AD. Immunophenotypic analysis of platelets. Curr Protoc Cytom. 2002 Feb; Chapter 6:Unit 6.10. PMID: 18770767.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  113. Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Pieper K, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J. 2001 Nov; 142(5):790-8. PMID: 11685164.
    Citations: 6     Fields:    Translation:HumansCells
  114. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL, Goldberg RJ, Michelson AD. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001 Oct; 38(4):1002-6. PMID: 11583872.
    Citations: 107     Fields:    Translation:HumansCells
  115. Frelinger AL, Furman MI, Krueger LA, Barnard MR, Michelson AD. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation. 2001 Sep 18; 104(12):1374-9. PMID: 11560852.
    Citations: 7     Fields:    Translation:HumansCells
  116. Claytor RB, Li JM, Furman MI, Garnette CS, Rohrer MJ, Barnard MR, Krueger LA, Frelinger AL, Michelson AD. Laser scanning cytometry: a novel method for the detection of platelet--endothelial cell adhesion. Cytometry. 2001 Apr 01; 43(4):308-13. PMID: 11260598.
    Citations: 3     Fields:    Translation:HumansCells
  117. Furman MI, Krueger LA, Frelinger AL, Barnard MR, Mascelli MA, Nakada MT, Michelson AD. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost. 2000 Sep; 84(3):492-8. PMID: 11019977.
    Citations: 11     Fields:    Translation:HumansCells
  118. Michelson AD, Barnard MR, Krueger LA, Frelinger AL, Furman MI. Evaluation of platelet function by flow cytometry. Methods. 2000 Jul; 21(3):259-70. PMID: 10873480.
    Citations: 36     Fields:    Translation:HumansCells
  119. Berkowitz SD, Frelinger AL, Hillman RS. Progress in point-of-care laboratory testing for assessing platelet function. Am Heart J. 1998 Oct; 136(4 Pt 2 Su):S51-65. PMID: 9778088.
    Citations: 1     Fields:    Translation:Humans
  120. Frelinger AL, Hillman RS. Novel methods for assessing platelet function. Am Heart J. 1998 May; 135(5 Pt 2 Su):S184-6. PMID: 9588398.
    Citations:    Fields:    Translation:HumansCells
  121. Rote WE, Mu DX, Roncinske RA, Frelinger AL, Lucchesi BR. Prevention of experimental carotid artery thrombosis by applaggin. J Pharmacol Exp Ther. 1993 Nov; 267(2):809-14. PMID: 8246155.
    Citations: 3     Fields:    Translation:AnimalsCells
  122. Wencel-Drake JD, Frelinger AL, Dieter MG, Lam SC. Arg-Gly-Asp-dependent occupancy of GPIIb/IIIa by applaggin: evidence for internalization and cycling of a platelet integrin. Blood. 1993 Jan 01; 81(1):62-9. PMID: 8417803.
    Citations: 7     Fields:    Translation:HumansCells
  123. Bajt ML, Ginsberg MH, Frelinger AL, Berndt MC, Loftus JC. A spontaneous mutation of integrin alpha IIb beta 3 (platelet glycoprotein IIb-IIIa) helps define a ligand binding site. J Biol Chem. 1992 Feb 25; 267(6):3789-94. PMID: 1371279.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  124. Bowditch RD, Tani PH, Halloran CE, Frelinger AL, McMillan R, Ginsberg MH. Localization of a PlA1 epitope to the amino terminal 66 residues of platelet glycoprotein IIIa. Blood. 1992 Feb 01; 79(3):559-62. PMID: 1370635.
    Citations: 2     Fields:    Translation:HumansCells
  125. Frelinger AL, Du XP, Plow EF, Ginsberg MH. Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J Biol Chem. 1991 Sep 15; 266(26):17106-11. PMID: 1894607.
    Citations: 80     Fields:    Translation:Cells
  126. Pidard D, Frelinger AL, Bouillot C, Nurden AT. Activation of the fibrinogen receptor on human platelets exposed to alpha chymotrypsin. Relationship with a major proteolytic cleavage at the carboxyterminus of the membrane glycoprotein IIb heavy chain. Eur J Biochem. 1991 Sep 01; 200(2):437-47. PMID: 1889410.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  127. Du XP, Plow EF, Frelinger AL, O'Toole TE, Loftus JC, Ginsberg MH. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell. 1991 May 03; 65(3):409-16. PMID: 2018974.
    Citations: 127     Fields:    Translation:HumansCells
  128. Ginsberg MH, Frelinger AL, Lam SC, Forsyth J, McMillan R, Plow EF, Shattil SJ. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies. Blood. 1990 Nov 15; 76(10):2017-23. PMID: 2242424.
    Citations: 22     Fields:    Translation:HumansCells
  129. Loftus JC, O'Toole TE, Plow EF, Glass A, Frelinger AL, Ginsberg MH. A beta 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science. 1990 Aug 24; 249(4971):915-8. PMID: 2392682.
    Citations: 89     Fields:    Translation:AnimalsCells
  130. Frelinger AL, Cohen I, Plow EF, Smith MA, Roberts J, Lam SC, Ginsberg MH. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem. 1990 Apr 15; 265(11):6346-52. PMID: 2318856.
    Citations: 67     Fields:    Translation:HumansCells
  131. Lam SC, Plow EF, D'Souza SE, Cheresh DA, Frelinger AL, Ginsberg MH. Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. J Biol Chem. 1989 Mar 05; 264(7):3742-9. PMID: 2465293.
    Citations: 19     Fields:    Translation:HumansCells
  132. Frelinger AL, Lam SC, Plow EF, Smith MA, Loftus JC, Ginsberg MH. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem. 1988 Sep 05; 263(25):12397-402. PMID: 2457583.
    Citations: 38     Fields:    Translation:HumansCells
  133. Loftus JC, Plow EF, Frelinger AL, D'Souza SE, Dixon D, Lacy J, Sorge J, Ginsberg MH. Molecular cloning and chemical synthesis of a region of platelet glycoprotein IIb involved in adhesive function. Proc Natl Acad Sci U S A. 1987 Oct; 84(20):7114-8. PMID: 2444974; PMCID: PMC299240.
    Citations: 16     Fields:    Translation:HumansCells
  134. Frelinger AL, Rutishauser U. Topography of N-CAM structural and functional determinants. II. Placement of monoclonal antibody epitopes. J Cell Biol. 1986 Nov; 103(5):1729-37. PMID: 2430977; PMCID: PMC2114365.
    Citations: 26     Fields:    Translation:AnimalsCells
  135. Watanabe M, Frelinger AL, Rutishauser U. Topography of N-CAM structural and functional determinants. I. Classification of monoclonal antibody epitopes. J Cell Biol. 1986 Nov; 103(5):1721-7. PMID: 2430976; PMCID: PMC2114397.
    Citations: 33     Fields:    Translation:AnimalsCells
  136. Frelinger AL, Zull JE. The role of the methionine residues in the structure and function of parathyroid hormone. Arch Biochem Biophys. 1986 Feb 01; 244(2):641-9. PMID: 3947084.
    Citations: 13     Fields:    Translation:AnimalsCells
  137. Frelinger AL, Zull JE. Oxidized forms of parathyroid hormone with biological activity. Separation and characterization of hormone forms oxidized at methionine 8 and methionine 18. J Biol Chem. 1984 May 10; 259(9):5507-13. PMID: 6715358.
    Citations: 11     Fields:    Translation:AnimalsCells
  138. Botti RE, Heath E, Frelinger AL, Chuang J, Roos BA, Zull JE. Specific cleavage of bovine parathyroid hormone catalyzed by an endopeptidase from bovine kidney. J Biol Chem. 1981 Nov 25; 256(22):11483-8. PMID: 7028735.
    Citations: 1     Fields:    Translation:AnimalsCells
  139. Roos BA, Lindall AW, Baylin SB, O'Neil JA, Frelinger AL, Birnbaum RS, Lambert PW. Plasma immunoreactive calcitonin in lung cancer. J Clin Endocrinol Metab. 1980 Apr; 50(4):659-66. PMID: 7364923.
    Citations: 5     Fields:    Translation:HumansCells
  140. Roos BA, Yoon MJ, Frelinger AL, Pensky AE, Birnbaum RS, Lambert PW. Tumor growth and calcitonin during serial transplantation of rat medullary thyroid carcinoma. Endocrinology. 1979 Jul; 105(1):27-32. PMID: 446409.
    Citations: 4     Fields:    Translation:Animals
  141. Roos BA, Lindall AW, Baylin SB, O'Neil J, Frelinger AL, Birnbaum RS, Lambert PW. Plasma immunoreactive calcitonin in lung cancer. Endocr Res Commun. 1979; 6(2):169-90. PMID: 228926.
    Citations: 3     Fields:    Translation:Humans
  142. Roos BA, Cooper CW, Frelinger AL, Deftos LJ. Acute and chronic fluctuations of immunoreactive and biologically active plasma calcitonin in the rat. Endocrinology. 1978 Dec; 103(6):2180-6. PMID: 748041.
    Citations: 4     Fields:    Translation:Animals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Frelinger's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (501)
Co-Authors (29)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.